Pharmaceutical Industry Reports Kidney Cancer Drugs Market | Page 2

REPORT DESCRIPTION
Kidney Cancer Drugs Market – Overview
CpG oligodeoxynucleotide (CpG ODN) is a synthetic oligodeoxynucleotide, which contains unmethylated CpG motifs
derived from bacterial DNA with immunostimulatory activities. CpG ODN is a short single-stranded synthetic DNA
molecule, which contains one of each of cytosine triphosphate deoxynucleotide and guanine triphosphate
deoxynucleotide that makes up the C component in the molecule.
The CpG motifs are considered pathogen-associated molecular patterns (PAMPs), as they are present in microbial
genomes in abundance, but are rarely present in vertebrate genomes. These CpG PAMPs are recognized by the pattern
recognition receptor (PRR) toll-like receptor 9 (TLR9), which is constitutively expressed only in B cells and
plasmacytoid dendritic cells (pDCs) in humans and other higher primates. CpG ODNs show great potential for
attachment in prophylactic vaccines designed to prevent infection. Various research companies are targeting synthetic
CpG ODN due to the type I pro-inflammatory response it produces and its successful use as vaccine adjuvants.
Increasing demand for vaccination across the globe is expected to contribute to significant growth of the CpG
oligodeoxynucleotide market over the forecast period. For instance, according to the UNICEF-Vaccination &
Immunization Statistics, in 2017, around 123 million children got immunized with lifesaving vaccines across the
world. Moreover, according to the Centers for Disease Control and Prevention (CDC), at least 3,153,876,236 doses of
vaccines were distributed in the U.S. from 2006 to 2016.
© Coherent market Insights. All Rights Reserved